Inactivating mutations in the cohesin complex component STAG2 have been reported in 5.9% of glioblastoma and at lower frequency in melanoma and Ewing's sarcoma (1) and several other cancer types [COSMIC; cancer.sanger.ac.uk/cancergenome/projects/cosmic/]. Here, STAG2 is linked to glioblastoma.